Six Firms Share the Top Band on Medical Device Deals

Device companies comparing medical device law firms will not find one adviser that dominates the work. Sartori & Partners data show 781 deals for medical device clients in the 12 months to October 2026, and the most active firm on them sits in the 21-40 band of deals advised. The tenth most active sits in the 11-20 band, one step below. That flat top changes how a general counsel should buy outside counsel. No firm has a volume lead the others cannot match, so the shortlist can be built on the team, the price and the conflicts position rather than on a claim to have done the most deals.

Six of the ten most active firms on medical device deals sit in the 21-40 band and the other four in the 11-20 band. Every firm in the device top 10 falls in one of those two bands of deals advised. Set that against pharma and biotech, where the most active firm sits in the 251-400 band and the tenth in the 61-100 band, or against the whole market, where the busiest firm is in the 1,200+ band.

Healthcare providers and payors show what a sector with a clear front-runner looks like: its most active firm sits in the 101-150 band, while the second is in the 21-40 band. Device work has no such gap. The device list also overlaps with life sciences: six of the ten device firms appear on the pharma and biotech list below, which means a company that already uses one of them for financings is buying from a firm that does both kinds of work.

For a device company the practical result is leverage. With no adviser far ahead on volume, a request for proposals can go to several of these firms on equal terms. The deciding points become the partner who will run the matter, the associates under that partner, the rate card, and whether the firm already acts for a direct competitor.

Capital markets deals were 43.9% of medical device deals, against 25.7% across all sectors: 1.7 times the market rate. In the Sartori & Partners deal records the device mix sits between its neighbors. Pharma and biotech runs higher, at 52.4%. Healthcare providers and payors run far lower, at 11.8%, with disputes and investigations first at 39.2%. Technology and software, at 23.3%, sits near the market.

The other device lines do not follow pharma. M&A is 21.4% of device deals, slightly above the market's 19.3% and above pharma and biotech at 17.5%. Disputes and investigations are 16.4% of device deals, well under the market's 25.0%. For the buyer, the firm that runs your offerings is the relationship you will use most often, and an M&A team earns its place on a device panel more clearly than on a pharma one.

The practice recorded on each deal tells the same story. Capital markets lawyers were credited on 44.4% of device deals, against 26.4% across the market, and corporate and M&A lawyers on 28.8%, against 23.3%. Intellectual property sits at 11.4%, almost level with the market's 11.1%. Banking and finance, at 4.4%, is below the market's 6.3%. One deal can carry several practices, so these shares overlap.

Health care regulatory work does not make the device deal list, yet a separate measure shows where it sits. Among lawyers with a device focus who changed firms in the past 12 months, health care was a practice of 25.0%, against 3.0% of lateral moves across the market. So buy two things separately. Price the capital markets work against firms with a deep issuer practice, and choose the regulatory lawyer by name, because deal tables will not show who handles clearances, recalls and agency inquiries.

Sartori & Partners figures put lawyers in Boston on 13.2% of medical device deals, against 10.1% of technology and software deals and 25.5% of pharma and biotech deals. Washington, home to the federal regulators, reads differently: its lawyers worked on 18.0% of device deals, just under technology's 19.6% and well under pharma's 25.0%. New York comes first for device work at 37.3%, close to technology's 38.7%.

Chicago, at 9.1% of device deals, is above its pharma share of 6.8%, and Paris, at 7.1%, appears among the device cities but not in the pharma or technology lists. San Diego shows the reverse: 5.3% for devices against 13.5% for pharma. These shares say where the work is done, and one deal can count in several cities. A device company's search for counsel should not stop at Boston and New York: Chicago matters more here than in pharma, and European deal work runs through Paris as well as London.

The count of medical device deals held flat (+6.9%) year on year in the settled 12-month windows, 810 against 758, while deals across all sectors rose 10.6%. Pharma and biotech deals rose 14.5% and healthcare providers and payors rose 13.4% over the same windows. Technology and software held flat (+4.6%).

A steady sector inside a rising market is a buyer's position. Device mandates are not getting harder for these firms to win, and none of the most active advisers has a volume lead to price on. Use the next panel review or engagement renewal to ask for fixed or capped fees on repeat capital markets work, where the steps are well known and the firm's learning curve is behind it.

Start with the shape of the market. Every firm in the device top 10 sits in the 11-20 or 21-40 band, so the decision is about people and price, not about finding the one firm that has done the most deals. Run a competitive process with a handful of firms from that list, and ask each to name the partner and senior associate who will staff your work.

Weight the panel toward capital markets. At 43.9% of device deals, offerings are the work you will buy most often, and the firm that runs them will see your company more than any other adviser. Pair that firm with an M&A team, since M&A is 21.4% of the sector's deals, and with a regulatory lawyer chosen by name rather than by deal credits.

Look beyond New York. Lawyers in Boston worked on 13.2% of device deals and lawyers in Chicago on 9.1%; a firm with real depth in either city deserves a place on the shortlist, next to the Washington lawyers who handle the agency side.